Pliant Therapeutics Announces Update on Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial
Pliant Therapeutics halted its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) due to an imbalance...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy manufacturing compliance Oncology Trials Opinion Parkinson's Disease Patient Stratification Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Pliant Therapeutics halted its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) due to an imbalance...
Celldex Therapeutics announced positive preclinical data for CDX-622, a bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and stem cell...
NKGen Biotech administered its expanded autologous NK cell therapy, troculeucel, to a stroke patient under an FDA-cleared compassionate use...
Oryzon Genomics has established primary and key secondary endpoints for its Phase III clinical trial of vafidemstat for Borderline...
Spectral Medical Inc. (TSX: EDT) announced an update on its Tigris Phase 3 trial, which is evaluating Polymyxin B...
MBX Biosciences completed enrollment in its Phase 2 Avail™ trial of canvuparatide, a parathyroid hormone (PTH) prodrug for chronic...
In this conversation with Miruna Sasu, President and CEO of COTA Healthcare, we explore the transformative power of real...
Aura Biosciences announced Phase 1 data from its trial of bel-sar (AU-011) for non-muscle invasive bladder cancer (NMIBC) will...
Voyager Therapeutics announced positive topline data from its single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody...
Traws Pharma announced positive topline results from a ferret study of tivoxavir marboxil, a single-dose oral antiviral for bird...